Advanced searches left 3/3

Type 2 Diabetes - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 09 June 2022

* If you want to update the article please login/register

CARdiomyopathy in Type 2 DIAbetes Mellitus

"The CARDIATEAM study will explore the uniqueness of DCM and its progression to heart failure with a reduced ejection fraction by recruiting a prospective CARDIATEAM cohort from existing cohorts with a defined set of selection criteria and including type2-Diabetes mellitus and non-diabetic patients with a large variety of demographic, metabolic, and cardiac epidemiological results," the researcher said.

Source link: https://clinicaltrials.gov/ct2/show/NCT04303364


Type 2 Diabetes Prevention Toolkit for Health-Care Professionals

"Approximately one third of Canadian children and adolescents can be classified as overweight or obese. " A primary care-based obesity treatment scheme may be a safe way to address obesity while also assisting in the prevention of Type 2 Diabetes and other co-morbidities. According to preliminary results, the introduction of the 5As of Adult Obesity Management will improve patient-to-patient interactions in weight management. Although this website is a useful tool for HCPs, focus groups have reported that HCPs would like an expanded version with realistic pictures of what a 5As framed encounter might look like in a crowded office environment. The investigators have produced six videos to analyze: Weight Science 101: Weight Science 101 will feature background information, as well as details on the driving factors that lead to body weight control. Video #5: ADVISE, AGREE, and ASSIST will address pediatric obesity management in the primary care setting, how to encourage patient involvement in the process, and how to sustain therapy. This review will look at the videos using pre and post questionnaires. This video, titled Video #6: Putting it All Together, will review each of the 5As and how to use them as a comprehensive tool for pediatric obesity management. The investigators need to determine the content, quality, and impact of HCPs' self-confidence/confidence, knowledge, and change in strategy in regards to tackling weight-related problems with pediatric patients and their families using the 5A framework with the questionnaires.

Source link: https://clinicaltrials.gov/ct2/show/NCT04126291


Genetics of Type 2 Diabetes in Diverse Populations

"This research protocol is designed to investigate the genetic causes of Type 2 Diabetes and other African disorders. " Multiple institutes in Northern Ireland have continuously funded this project, including an R01 grant from the NIDDK to Dr. Rotimi when he was a Professor at Howard University, which has been funded for over a decade. Although the previous phases of this investigation included related individuals, we are now only recruiting unrelated T2D cases and controls in order to promote genome-wide association studies or similar types of genetic analyses for which unrelated datasets are most useful. In addition, these samples will be used to investigate genetic variation in the context of how people of various originstry respond to drugs and other environmental causes, as well as how population history has influenced population history. These studies, in total, are intended to expand our understanding of the genetic basis of T2D in African people. Given recent events, it is also anticipated that this resource will be used to support multiple collaborations between Dr. Rotimi's lab, several NIH intramural researchers, and non-NIH scientists. Each new population from Africa and beyond may be included to this report over time to expand the focus on individuals from diverse ancestral origins; each subsequent group will use the same techniques as in current African research.

Source link: https://clinicaltrials.gov/ct2/show/NCT00837122


Natural History of Type 2 Diabetes Mellitus in Children and Young Adults

"Background: Type 2 diabetes mellitus is a disorder that is characterized by insulin resistance and chronic inability of insulin-secret beta-cells. " Patients with childhood onset T2DM are at a significant risk of diabetes-related morbidity and mortality, as well as potential increased beta-cell dysfunction. Methods: In a cross-sectional and longitudinal fashion, children and young adults with type 2 diabetes ages 8 to 25 years will be investigated. For comparison purposes: healthy lean controls, and overweight/obese controls will be tested in two control groups without diabetes. In a pilot study of artificial sweeteners, patients with type 1 diabetes will be tested using oral glucose tolerance and mixed meal tests.

Source link: https://clinicaltrials.gov/ct2/show/NCT00445627


Project Dulce for Filipino-Americans With Type 2 Diabetes

"Among Asian Americans, Filipino Americans have the second highest T2DM prevalence and have an elevated risk of developing complications due to a lack of involvement in health-safety practices and increased social and environmental barriers to optimal self-management. " Project Dulce is an American Diabetes Association-recognized adult T2DM management service designed to meet the needs of a large and ethnically diverse San Diego community. Previous studies have shown that Project Dulce team-care improves clinical administration and saves money, as well as that peer education alone improves clinical outcomes in Hispanics with T2DM. The peer education materials were expanded by the Dulce Digital program to extend the care team's reach by text messages derived from the Project Dulce curriculum, including medication reminders and blood glucose monitoring prompts, more recently. With T2DM, this study aims to culturally adapt Project Dulce and Dulce Digital for FAs. This report will explore the impact of the culturally adaptable Project Dulce + Dulce Digital in improving diabetes knowledge, attitudes, and beliefs among FAs with T2DM; review of the culturally modified Project Dulce + Dulce Digital in raising HbA1C and self-management habits; and evaluate the acceptability and feasibility of the culturally adapted Project Dulce Digital, which was delivered by FA peer educator to FA patients with T2DM; and determine the acceptability and feasibility.

Source link: https://clinicaltrials.gov/ct2/show/NCT05378620


Memory Advancement by Intranasal Insulin in Type 2 Diabetes

"The investigators plan a placebo controlled trial determining the long-term effects of intranasal insulin on cognition and memory in type 2 diabetes and non-DM populations. " Aim 1: To determine whether INI-treated type 2 DM adults have greater recall and operation of specific cognitive domains, a faster dual-task gait speed, and improved daily life quality than placebo-treated and non-DM adults. 60 DM subjects were treated with insulin; 60 DM subjects were treated with placebo; and 45 control subjects were treated with placebo; and 45 control subjects were treated with placebo. In a clinical phenotype of cognitive decline and insulin resistance that occurs with normal aging, non-DM companies would include INI effects in a clinical phenotype of cognitive decline and insulin resistance that occurs with normal aging. In the DM group vs. the placebo and non-DM groups, the investigators will determine a phenotype that can show a clinically relevant response to INI therapy and determine time-dependent trajectories of INI effects on cognition. In 40 DM patients pre- and post-intervention and post-INI placement, the investigators will investigate long-term effects on regional perfusion, vaping, and resting functional connectivity, as well as their relationships to cognitive outcomes. The investigators will continue glucose monitoring during intravascular or placebo therapy for the first week of INI or placebo therapy in the first 20 DM patients treated with subcutaneous insulin, beginning at 9/25/2017 for 1 week, measuring the INI's effect on glucose control, hypoglycemic episodes, and body weight in the first 20 patients treated with subcutaneous insulin.

Source link: https://clinicaltrials.gov/ct2/show/NCT02415556


Precision Medicine for Preventing Type 2 Diabetes: a Step Forward (PRE-MED2)

1. toexplore the possibility of a more accurate subgroup distinction in prediabetes, which may lead to a more effective preventive action; 2. to explore the use of mHealth to reduce or delay the development of type 2 diabetes in a subgroup of patients at an elevated risk of type 2 diabetes; 2. to explore the effects of such policies based on individual characterization. Based on an opportunistic approach, 1200 patients at risk of type 2 diabetes will be recruited at GP's offices, Pharmacies, as well as via media. In addition, the database for data processing and patient interventions will be enhanced. In a phase 3 clinical trial, themHealth automated behavioral assessment, website, and smartphone will be tested and validated in two high-risk populations of obese non-diabetic subjects and women with previous gestational diabetes in two separate high-risk populations. During the intervention trial's last two weeks, all participants will be provided with the same wearable device used for initial testing of the same initial parameters. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05147961


Therapeutic Targets in African-American Youth With Type 2 Diabetes

"Type 2 diabetes in youth is a common public health issue thatdisproportionately affects minority children. " African-Americans have the highest complication rates among minority youth, but the reasons underlying this health inequalities are not fully understood. Metformin therapy is the only oral diabetes drug approved for use in children with type 2 diabetes. Improving youth outcomes in youth requires knowing how drugs such as metformin work in youth and why it does not work in some populations. Liraglutide has been approved to treat type 2 diabetes in patients ten years and older as an adjunct to diet and exercise. Liraglutide may be a good early treatment in youth with type 2 diabetes because it may reduce glucose produced by the liver. In addition, we will investigate the relationship between known variations in metformin transport and action with changes in gluconeogenesis and metformin lowering results, as well as investigating the role of gut bacteria in metformin's glucose-lowering function. The purpose of the study is a parallel-randomized intervention trial of African-American youth with type 2 diabetes who are not on insulin therapy and who are within 5 years of diagnosis. Following Visit 2, participants will begin the study drug immediately after Return to visit 2 and remain on the study drug for 12 weeks. This multi-site initiative aims to resolve diabetes in African-American youth by determining the way these diabetes agents' work to inform precision medicine research.

Source link: https://clinicaltrials.gov/ct2/show/NCT02960659


Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes

"Bariatric groups will include adult men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy and followed at 0, 4 months, 8 months, 1 year, and three years after surgery, and the control group will consist of 30 overweight people with or without diabetes or prediabetes and measured at a single visit," says the control group.

Source link: https://clinicaltrials.gov/ct2/show/NCT03455868

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions